ADAR1 Capital Management LLC Takes $1.33 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• ADAR1 Capital Management acquired 133,000 BioCryst Pharmaceuticals shares worth approximately $1.33 million, representing about 0.05% of the company. Institutional investors collectively own 85.88% of BCRX.
• BioCryst reported quarterly EPS of $0.30, beating the $0.15 consensus estimate, while revenue rose 33.6% year over year to $218.25 million, above expectations of $183.28 million.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $20.60, compared with the stock’s recent price of $9.83.

ADAR1 Capital Management LLC bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 133,000 shares of the biotechnology company's stock, valued at approximately $1,330,000. ADAR1 Capital Management LLC owned about 0.05% of BioCryst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Larson Financial Group LLC raised its stake in shares of BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 3,267 shares in the last quarter. Allworth Financial LP acquired a new position in BioCryst Pharmaceuticals during the second quarter worth $52,000. Focus Partners Wealth bought a new stake in BioCryst Pharmaceuticals during the third quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. raised its position in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 2,115 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $81,000. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Trading Up 1.5%

BioCryst Pharmaceuticals stock opened at $9.83 on Wednesday. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.56. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.22. The stock's 50 day moving average is $9.66 and its 200-day moving average is $9.00.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to analysts' expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The firm's revenue for the quarter was up 33.6% compared to the same quarter last year. During the same period last year, the firm posted $0.15 EPS. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

BCRX has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Weiss Ratings reiterated a "hold (c)" rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Cantor Fitzgerald boosted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 30th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Finally, Citizens Jmp upped their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a "market outperform" rating in a research note on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $20.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.